Formulae Sample Clauses

Formulae. (A) Single Productions, Not Part of a Series Calculate the full value of all seats in each ticket price category (i.e. the price of ticket to purchaser) to derive the box office potential for each performance. Select the maximum number of performances given in any one (1) week (i.e. a Monday to Sunday period as defined in Clause 18:30) and add their total potential together to derive the gross weekly box office potential. The price of the ticket to purchaser is the full non-discounted price for the seat. However, Theatre for Young Audience companies which submit Company Category Calculations in accordance with Article 55:00, for productions that do not contain a touring element, may use the student ticket price for performances beginning before 4:30 p.m. For performances beginning after 4:30 p.m., the calculation will be based on half the available seats at the full adult non-discounted ticket price, and the remaining half of the available seats at the children’s or student ticket price. Subtract Entertainment Tax (if any), Goods and Services Taxes (hereinafter called "GST") and Capital Improvement Fund surcharges (hereinafter called "CIF") to derive the net box office potential. (PACT members may apply to PACT and Equity for the exclusion of capital improvement fund ticket surcharges and other venue surcharges from the price of the ticket. This application should be made prior to preparing the Company Category Calculation.) Compare to the table in Clause 15:02 to establish Company Category.
Formulae. GILEAD represents and warrants that the Specifications for the Product are its property and that GILEAD may lawfully disclose such Specifications to APO. GILEAD further represents and warrants that any trademarks utilized by APO in connection with the Product are its property and may be lawfully used as directed by GILEAD. GILEAD further represents and warrants that the Specifications for the Product conform to all applicable laws and regulations, and that the Product if labeled and formulated in accordance with such Specifications and Manufactured in compliance with this Agreement (i) may be lawfully sold and distributed in every jurisdiction in which GILEAD markets the Product, (ii) will be fit for the purpose intended, and (iii) subject to labeling and application in accordance with applicable laws will be safe for human consumption.
Formulae. Figures, formulae, and trial-balance figures may be included within text. For figure columns, formulae are entered directly but text requires the formulae to be between square brackets "[" and "]". The results of formulae are then incorporated within the text of the accounts during accounts production. The format of formulae within the brackets is identical to cell formulae. See Formulae and Trial Balance Figures later. Database entries
Formulae. Promptly following Closing, Seller agrees to use commercially reasonable efforts to provide Buyer with any other formulae that may have been inadvertently omitted from Schedule 2.1.1.9, including, but not limited to, written set up sheets, set up procedures and operator know how (to the extent documented in writing) related to the formulae set forth on Schedule 2.1.1.9. For the avoidance of doubt, the parties acknowledge that Seller has possession of and access to certain customer-owned formulae. Although the parties agree that these customer-owned formulae are not part of the Purchased Assets, the customer-owned formulae that Seller has possession of and access to shall be listed separately on Schedule 2.1.1.9, and Seller shall grant possession of and access to such listed customer-owned formulae to Buyer at Closing. Buyer agrees to use reasonable care with respect to the customer-owned formulae in compliance with any applicable contracts with respect thereto.
Formulae. The abbreviations used herein shall have the meaning as defined below; [*****] [*****] [*****] [*****] [*****] FORMULAE Unit UTILITY ‘000 M3 water - industrial = [***** ] * [*****] ‘000 M3 water - decarbonated = [***** ] * [*****] + [***** ] ‘000 M3 water - demineralised = [***** ] * [*****] + [***** ] ‘000 MT Steam - HP (*) = [***** ] * [*****] + [***** ] * DemW + [***** ] ‘000 MT Steam - MP (*) = [***** ] * [*****] + [***** ] * DemW + [***** ] ‘000 MT Steam - LP (*) = [***** ] * [*****] + [***** ] * DemW + [***** ] ‘000 M3 Eau Chaudiere = [***** ] * [*****] + [***** ] * DemW + [***** ] ‘000 M3 Condensats [***** ] * [*****] + [***** ] * DemW + ‘000 M3 Air = [***** ] * [*****] + [***** ] * SRF ‘000 M3 water - cooling = [***** ] * [*****] + [***** ] * RW + [***** ] NB: Formulae subject to periodical review as appropriate and in agreement with steering committee [*****] [Confidential Treatment Requested]
Formulae. The Amount of variation in prices in several components (labour material etc.) shall be worked out by the following formulae :
Formulae. Genelabs represents and warrants that Genelabs Specifications for each of the Products are its or its Affiliate's property and that Genelabs may lawfully disclose Genelabs Specifications to Patheon. Genelabs further represents and warrants that any trademarks utilized in connection with any of the Products are its or its Affiliate's property and may be lawfully used as directed by Genelabs. Genelabs further represents and warrants that Genelabs Specifications for all Products conform to all applicable laws and regulations, and that the Products, if labeled and formulated in accordance with Genelabs Specifications and manufactured in compliance Patheon Manufacturing Requirements, (i) may be lawfully sold and distributed in every jurisdiction covered by this Agreement in which Genelabs markets such Products, (ii) will be fit for the purpose intended, and (iii) will be safe for human consumption.

Related to Formulae

Processes Any employer, employee, trade union or employer’s association may at any point in time apply for an exemption from any of the provisions of this Collective Agreement. The applicant is required to complete and submit in writing with the relevant office of the Council, a fully and properly completed prescribed application for exemption form, accompanied by all relevant supporting documentation.
Personnel Information Employee shall not divulge or discuss personnel information such as salaries, bonuses, commissions and benefits relating to Employee or other employees of Employer or any of its subsidiaries with any other person except the Executive Committee and the Board of Directors of Employer.
Technical SPECIFICATIONS
Protocols The Parties may, at a Conference of the Parties, adopt a Protocol to this Agreement.
Strategies MAEM’s strategies with respect to all Offers, Third Party Contracts and all Scheduling activities shall be consistent with:
Discoveries Any and all inventions, discoveries, improvements, designs, methods, systems, developments, know how, ideas, suggestions, devices, trade secrets and processes (collectively, “Discoveries”), whether patentable or not, which are discovered, disclosed to or otherwise obtained by Executive during Executive’s employment with the Company, are confidential, proprietary information and are the sole and absolute property of the Company. Executive shall immediately disclose and hereby assigns to the Company all such Discoveries and shall assist the Company in making any application in the United States and in foreign jurisdictions for patents of any kind with respect thereto. Whenever requested to do so by the Company, Executive shall execute any and all applications, assignments, or other instruments that the Company may deem necessary to protect the Company’s interest therein. Notwithstanding the fact that the Company may request additional assignment and assistance in applications, the assignments made in this Section 8 are adequate to cause an assignment of Executive’s interest in any Discoveries.
Manuals Simultaneous with delivery, all Product shall be furnished with standard manuals (e.g. maintenance, parts and operational manuals) as would normally accompany such Product(s). Manuals may be provided printed and bound, on CD, or at an online website. If paper manuals are provided, an Authorized User shall be able to opt not to receive extra copies of documentation when ordering multiple units. This arrangement should be agreed upon between the Contractor and the Authorized User prior to order. An Authorized User may also want to purchase additional sets of documentation, if needed. If the provision of additional sets of documentation is subject to a separate cost, the Contractor must so advise the Authorized User at the time of order. Contractor shall also ensure that the part numbers associated with this provision of additional sets of documentation are available to the Authorized User on the OEM Specifications or Contractor-published price list. Further, where documentation is provided either in printed or electronic format, Authorized User shall be entitled to make copies to the extent necessary to fully enjoy the rights granted under the resulting Contract provided that the Authorized User reproduces the copyright notice and any other legend of ownership on any copies made.
Data The information set forth in the related Mortgage Loan Schedule, including any diskette or other related data tapes sent to the Purchaser, is complete, true and correct in all material respects. The information on the Mortgage Loan Schedule and the information provided are consistent with the contents of the originator's records and the Mortgage File. The Mortgage Loan Schedule contains all of the required fields. Any seller or builder concession has been subtracted from the Appraised Value of the Mortgaged Property for purposes of determining the LTV and CLTV. Except for information specified to be as of the origination date of the Mortgage Loan, the Mortgage Loan Schedule contains the most current information possessed by the originator. No appraisal or other property valuation referred to or used to determine any data listed on the Mortgage Loan Schedule was more than 3 months old at the time of the Mortgage Loan closing.
Compositions any corporate action, legal proceedings or other procedures or steps are taken, or negotiations commenced, by any Relevant Party or by any of its creditors with a view to the general readjustment or rescheduling of all or part of its indebtedness or to proposing any kind of composition, compromise or arrangement involving such company and any of its creditors; or
Methods We assessed the inter-reader variability of different methods for quantification of 18F-FDG uptake in 43 patients with carotid artery stenosis ≤70%. Two independent readers delineated the plaque and collected maximum standardized uptake value (SUVmax) from all axial PET slices containing the atherosclerotic plaque. Results: Uptake values with and without background correction were calculated and intraclass correlation coefficients were highest for uncorrected uptake values (0.97–0.98) followed by those background corrected by subtraction (0.89– 0.94) and lowest for those background corrected by division (0.74–0.79). Conclusion: Quantification methods without background correction have the highest inter-reader agreement for 18F-FDG PET of carotid artery plaque inflammation. The use of the single highest uptake value (max SUVmax) from the plaque will facilitate the method’s clinical utility in stroke prevention. Keywords 18F-FDG PET/CT, carotid stenosis, stroke, cardiology, primary and secondary stroke prevention, imaging of the brain and arteries, quantification method Date received: 30 June 2020; Revised 28 October 2020; accepted: 24 November 2020 Introduction Ischemic strokes caused by thromboembolism from an unstable atherosclerotic plaque in the carotid artery can be prevented by carotid endarterectomy (CEA).1–3 Patients are selected for CEA based on the Positron emission tomography (PET) imaging of atherosclerosis has been rapidly evolving since the first reports of 2-deoxy-2-(18F)-fluoro-D-glucose (18F-FDG) uptake localized to the inflammatory degree of carotid artery stenosis and presence or absence of cerebral ischemic symptoms. In recent years it has become increasingly clear that the degree of stenosis alone is not the best predictor of stroke risk. This has led to the concept of the ‘unstable plaque’ describing carotid plaques that carry high risk of stroke irrespective of the degree of artery stenosis and increased focus on factors that destabilize the plaque. Inflammation plays a key role in the development of an unstable plaque.4–6 1Department of Nuclear Medicine, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway 2Institute of Clinical Medicine, University of Oslo, Oslo, Norway 3Department for Research and Development, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Oslo, Norway 4Department of Neurology, Oslo University Hospital, Oslo, Norway Corresponding author: Kjersti Johnsrud, Division of Radiology and Nuclear Medicine, Oslo University Hospital, Postbox 4950 Nydalen, 0424 Oslo, Norway. Email: kjersti@slogum.no Creative Commons CC BY: This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https:// creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). macrophage rich areas in carotid artery plaques.7 The goal of the imaging technique is to detect carotid pla- ques that are at high risk of rupture and therefore carry high risk of stroke. 18F-FDG PET for the detection of unstable plaques is not in clinical use,8 partly due to lack of feasible PET protocols and consensus regarding imaging procedure, method for 18F-FDG uptake quan- tification and assessment of stroke risk, although sev- eral recommendations exist.9,10 PET is an imaging modality with limited anatomical information, and it might therefore be challenging to define the vessel- segment-of-interest. Computed tomography angiogra- phy (CTA) is often used together with 18F-FDG PET when assessing patients with carotid artery stenosis, but selection of the plaque area for uptake measure- ments varies.11–13 A requirement for introducing a diagnostic method into clinical routine is high inter- reader agreement. Inter-reader agreement has been studied for a few selected uptake parameters with gen- eralized vascular inflammation14,15 and in patients with symptomatic carotid stenosis,12,13 but to our knowl- edge no study has compared inter-reader agreement for different quantification methods. The aim of this study was to assess inter-reader var- iability of different methods used for quantification of 18F-FDG uptake at PET/CT of carotid artery plaques. Materials and methods Study population ≤ The study cohort consisted of forty-three patients with ultrasound-confirmed atherosclerosis with internal carotid artery stenosis 70% according to consensus criteria of the Society of Radiologists in Ultrasound.16 Patient characteristics are summarized in Table 1. There were 30 men (66 T 9 years) and 13 women (67 T 8 years) with a mean age of 66.2 years. The study protocol conformed with the ethical guidelines of the 1975 Declaration of Helsinki and was approved by the Norwegian Regional Committee for Medical and Health Research Ethics South-East A. Written informed consent was obtained from all patients prior to study inclusion. 18F-FDG PET/CT examination × After a minimum of six hours fasting the patients were injected with 5 MBq/kg 18F-FDG and blood glucose, weight, and height were recorded. After approximately 90 minutes a two-bed position PET/CT from the base of the skull to the aortic arch was performed with 15 minutes per bed position using a hybrid PET/CT scanner (Siemens Biograph 64, Siemens Medical Systems, Erlangen, Germany). The PET images were acquired with a 256 256 matrix and the images were reconstructed to two millimetre thick slices, with four iterations/eight subsets ordered subset expectation– maximization (OSEM) algorithm and Gaussian post-reconstruction filter with 3.5 mm full width half maximum (FWHM). In addition to a non-contrast CT for attenuation correction a CTA with contrast filling of the arteries (minimum 40 mL Iomeron (iodine 350 mg/ mL; Bracco Imaging S.P.A, Milan, Italy) or Visipaque (iodine 320 mg/mL); GE Healthcare, Chicago, USA) was acquired immediately after the PET when still lying in the scanner for 16 of the 43 patients. For 24 patients CTA was performed at other radiologic depart- ments. For three patients no CTA was available when the PET images were analysed. Image analyses and 18F-FDG quantification The images were assessed with Hybrid Viewer 2.0 soft- ware (Hermes Medical Solutions AB, Stockholm, Sweden). Two experienced nuclear medicine senior consultants independently evaluated the 18F-FDG PET/CT examinations. The two readers (R1 and R2) did not undergo any joint training before assessing the images, but they agreed on how to perform the analy- ses. The instructions were to use the CTA as guide for drawing the region of interests (ROIs) on the fused slices (PET and non-contrast CT). The plaque was defined as vessel wall thickening and a lumen contrast-filling defect on CTA.11 The ROIs were drawn around the entire vessel wall and lumen on all plaque-containing axial PET slices (Figure 1). For patients without CTA available, the plaque was defined as vessel wall with calcification and fat deposits in the level of the carotid bifurcation. Uptake in structures close to the plaque (e.g. lymph nodes, paravertebral muscles or salivary glands) that could falsify the Table 1. Patient characteristics (n ¼ 43).* T T Age, years; mean SD 66.2 8.4 Sex, male; n (%) 30 (69.8) Blood glucose, mmol·L–1; mean T SD (range) 6.8 T 2.2 (4.9 – 14.9) Bodyweight, kg; mean T SD (range) 82.4 T 15 (55 – 110) Body mass index, kg/m2; mean T SD (range) 27.5 T 4.5 (19.9 – 34.8) *The patient material is included in previously published studies.18,19 plaque uptake values were excluded from the ROI. The number of plaque-containing slices for each patient was recorded. The pixel values in the PET images were converted into SUV and normalized to lean body mass.17 SUVmax in all plaque containing ROIs were recorded. Background blood pool activity was obtained from four ROIs placed in the lumen of the jugular vein away from structures with 18F-FDG uptake but preferably in the same craniocaudal level as the plaque. The background was calculated as the mean of the SUVmean in these four ROIs. Five different measures of 18F-FDG uptake were calculated, as pre- viously described in detail:18